Small molecules that target RNA structures within the CoV genome

​

Chemical structure of the three lead molecules derived from the focused library screen against OC43-infected Vero E6 cell screening (Zafferani et al 2021)

Invention Summary:

The SARS-CoV-2 pandemic, and the likelihood of future coronavirus pandemics, emphasized the urgent need for development of novel antivirals. Small-molecule chemical probes offer both to reveal aspects of virus replication and to serve as leads for antiviral therapeutic development.

Inventors from Rutgers, Case Western University, and Duke University have invented small molecules intended to serve as lead compounds for CoV RNA-targeted antivirals and chemical probes to further understand CoV RNA biology. Specifically, these are the first small molecules aimed at targeting RNA structures within the 5’-UTR and proximal region of the CoV genome. An amiloride-based small molecule library was screened and select compounds were found that potently inhibited replication competent SARS-CoV-2 as evident in the decreased levels of cell free virions in cell culture supernatants of treated cells.

Market Applications:

• Effective CoV antiviral therapeutics

Advantages:

• First small molecules aimed at targeting RNA structures within the 5’-UTR and proximal region of the CoV genome
• Foundation for effective CoV antivirals
• Probes for better understanding CoV RNA biology to apply to this pandemic and prepare for those in the future

Publications: •    Zafferani et al 2021

Intellectual Property & Development Status: PCT patent application filed and pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships contact marketingbd@research.rutgers.edu